PPARs and heart diseases
Takano, H.; Komuro, I.
Nihon Rinsho. Japanese Journal of Clinical Medicine 63(4): 659-664
2005
ISSN/ISBN: 0047-1852 PMID: 15828234 Document Number: 594221
After it has been reported that activation of PPARalpha or PPARgamma suppresses production of proinflammatory cytokines, medical interest in PPARs have grown and a huge research effort has been concentrated. Synthetic antidiabetic thiazolidinediones (TZDs) and natural prostaglandin D2 (PGD2) metabolite, 15d-PGJ2, are well known as ligands for PPARgamma. Hyperlipidemic drugs (fibrates) are synthetic PPARalpha ligands. Recent studies suggest that ligands of PPAR not only regulate glucose and lipid metabolism but also have pleiotropic effects on many tissues and cell types. Ligands of PPARs may become therapeutic agents useful in the prevention of cardiovascular diseases beyond their effects on glucose and lipid metabolism. This review will focus on the latest developments in the PPARs field and the roles of PPAR-dependent pathway in cardiovascular diseases.